Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Organised by The MDS Foundation, the International Congress on Myelodysplastic Syndromes (MDS 2021) will take place from 23-26 September 2021 as a virtual event. VJHemOnc are pleased to be an official media partner with the MDS Foundation for the International Congress.

MDS 2021

23–26 September 2021 | Virtual Meeting

MDS 2021

23–26 September 2021 | Virtual Meeting
Organised by The MDS Foundation, the International Congress on Myelodysplastic Syndromes (MDS 2021) will take place from 23-26 September 2021 as a virtual event. VJHemOnc are pleased to be an official media partner with the MDS Foundation for the International Congress.
Update on lenalidomide for MDS 7:32
Update on lenalidomide for MDS
Valeria Santini • 23 Sep 2021
Novel targets in low-risk MDS 1:27
Novel targets in low-risk MDS
Sophie Park • 22 Sep 2021
Assessing response to ESAs and alternative therapies 5:25
Assessing response to ESAs and alternative therapies
Sophie Park • 22 Sep 2021
ESAs for the management of lower-risk MDS 2:37
ESAs for the management of lower-risk MDS
Sophie Park • 22 Sep 2021
Key advances in MDS management 1:22
Key advances in MDS management
Sandra Kurtin • 22 Sep 2021
The role of immune checkpoint inhibitors in MDS 4:27
The role of immune checkpoint inhibitors in MDS
Shahram Kordasti • 22 Sep 2021
Improving our understanding of MDS for better disease management 2:27
Improving our understanding of MDS for better disease management
Sandra Kurtin • 22 Sep 2021
Inflammatory signaling in the pathogenesis of MDS 3:19
Inflammatory signaling in the pathogenesis of MDS
David Sallman • 14 Sep 2021
SF3B1 mutant MDS 2:24
SF3B1 mutant MDS
David Sallman • 14 Sep 2021
Immunotherapy in MDS 4:44
Immunotherapy in MDS
David Sallman • 14 Sep 2021
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML 2:58
Long-term follow-up: Phase II study of APR-246 + aza in TP53-mutated MDS & AML
Thomas Cluzeau • 20 Sep 2021
Integrated approaches to the diagnosis of MDS & MPNs 2:40
Integrated approaches to the diagnosis of MDS & MPNs
Anne Tierens • 16 Sep 2021
Optimizing transfusion support in MDS 3:02
Optimizing transfusion support in MDS
Yulia Lin • 17 Sep 2021
Classification of high-risk mutations in MDS 10:18
Classification of high-risk mutations in MDS
Moshe Mittelman • 13 Sep 2021
Clinical targets for successful iron chelation therapy 2:08
Clinical targets for successful iron chelation therapy
Heather Leitch • 15 Sep 2021
The immune system’s role in higher-risk MDS 6:05
The immune system’s role in higher-risk MDS
Shahram Kordasti • 22 Sep 2021
The content of VJHemOnc is intended for healthcare professionals